← Eichor
Condition: Nonsmall Cell Lung Cancer Stage Ii Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Nonsmall Cell Lung Cancer Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
NA · 4 location(s) · Thomas Jefferson University · NCT05502523A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Phase N/A · 1 location(s) · AIO-Studien-gGmbH · NCT02622581Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Phase 2 · 3 location(s) · Tang-Du Hospital · NCT06864624Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Phase 2 · 3 location(s) · Jianxing He · NCT07492342Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Phase 2 · 1 location(s) · Ji Yongling · NCT06379087A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
NA · 1 location(s) · All India Institute of Medical Sciences · NCT07565987Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell
Phase 1/Phase 2 · 9 location(s) · National Cancer Institute (NCI) · NCT07012031A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of
NA · 1 location(s) · Northwestern University · NCT05802186D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1
Phase 2 · 2 location(s) · Ruijin Hospital · NCT06269211Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Im
Phase 2 · 1 location(s) · Wake Forest University Health Sciences · NCT04253964Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer
Phase N/A · 4 location(s) · Scientific Institute San Raffaele · NCT06737107Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-smal
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06730295Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Vestre Viken Hospital Trust · NCT05344209Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06918132Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2 · 97 location(s) · AstraZeneca · NCT05061550A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Sma
Phase N/A · 1 location(s) · Yonsei University · NCT06907160Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06793813A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell L
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT05487391Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Phase 2 · 3 location(s) · Maastricht University Medical Center · NCT06401824A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Re
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT05991206A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
NA · 1 location(s) · Mayo Clinic · NCT06122064
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.